MELBOURNE, March 31, 2013: Access to the IMAGINE Phase 2 clinical trial investor conference call hosted on Monday 31st March Australian EDT is available via Open Briefing.

FEBRUARY 2014: MELBOURNE, Australia and NEW YORK, USA: US-based equity research analyst George B. Zavoico, Managing Director of H.C. Wainwright & Co, has published a report on Prana Biotechnology's (ASX:PBT / NASDAQ:PRAN) Phase 2 trial of PBT2 in patients with Huntington's disease, Reach2HD.

FEBRUARY 2014: MELBOURNE, Australia and NEW YORK, USA: Prana Biotechnology (ASX:PBT / NASDAQ:PRAN) has prepared a presentation for investors regarding the results of its Phase 2 clinical trial of PBT2 in patients with Huntington's disease.

FEBRUARY 2014: MELBOURNE, Australia and NEW YORK, USA: Prana Biotechnology (ASX:PBT / NASDAQ:PRAN) has today announced the results of its Reach2HD Phase 2 clinical trial investigating PBT2 as a treatment for Huntington disease.

FEBRUARY 2014: Prana Biotechnology will hold an investor conference call and webcast for professional investors on Wednesday 19th February at 9.30am Australian Eastern Daylight Savings Time (Tuesday 18th February US EST 5.30pm; US PST 2.30pm) to discuss the results of its Reach2HD Phase 2 clinical trial investigating PBT2 as a treatment for Huntington disease.

JANUARY 2014: Prana Biotechnology (ASX:PBT/ NASDAQ:PRAN), a leading innovative drug developer targeting disease modification in neurodegenerative disease, is commencing a non-deal investor roadshow in the United States with Credit Suisse.